ethyl 4-(4-bromophenyl)-1-(4-methoxy-4-oxobutyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

• ChemBase ID: 154720
• Molecular Formular: C19H23BrN2O5
• Molecular Mass: 439.30032
• Monoisotopic Mass: 438.07903385
• SMILES: CCOC(=O)C1=C(N(C(=O)NC1c1ccc(cc1)Br)CCCC(=O)OC)C
• Canonical SMILES: CCOC(=O)C1=C(C)N(C(=O)NC1c1ccc(cc1)Br)CCCC(=O)OC
• InChI: InChI=1S/C19H23BrN2O5/c1-4-27-18(24)16-12(2)22(11-5-6-15(23)26-3)19(25)21-17(16)13-7-9-14(20)10-8-13/h7-10,17H,4-6,11H2,1-3H3,(H,21,25)
• InChIKey: YFZRMRYVWWUQME-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: ethyl 4-(4-bromophenyl)-1-(4-methoxy-4-oxobutyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
• IUPAC Traditional name: ethyl 4-(4-bromophenyl)-1-(4-methoxy-4-oxobutyl)-6-methyl-2-oxo-3,4-dihydropyrimidine-5-carboxylate
• Synonyms: 4-(4-Bromophenyl)-5-(ethoxycarbonyl)-3,4-dihydro-6-methyl-2-oxo-1(2H)-pyrimidinebutanoic acid methyl ester; SW02

Database IDs

• CAS Number: 1010820-68-4
• MDL Number: MFCD17215960
• PubChem SID: 162248858
• PubChem CID: 44454748

CALCULATED PROPERTIES

• Acid pKa: 12.598881
• H Acceptors: 3
• H Donor: 1
• LogD (pH = 5.5): 2.3822823
• LogD (pH = 7.4): 2.3822799
• Log P: 2.3822823
• Molar Refractivity: 104.2615 cm^3
• Polarizability: 40.067127 Å^3
• Polar Surface Area: 84.94 Å^2
• Rotatable Bonds: 9
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: ≥20 mg/mL
• Apperance: white to off-white powder

Safety Information

• European Hazard Symbols: Toxic (T)
• German water hazard class: 3
• Risk Statements: 25
• Safety Statements: 45
• GHS Pictograms: GHS06
• GHS Signal Word: Danger
• GHS Hazard statements: H301
• GHS Precautionary statements: P301 + P310
• Storage Temperature: 2-8°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C19H23BrN2O5

DETAILS

Sigma Aldrich - S5951

Biochem/physiol Actions
SW02 is a specific activator/agonist of Hsp70. Hsp70 is of particular interest in diseases caused by protein misfolding, such as tau and Aβ in Alzheimer′s. SW02 increases Hsp70 ATPase activity, resulting in increased tau protein but not other disease-related proteins in cells. Hsp70 prevents aggregation of Aβ peptide, as shown by treatment with SW02.